Arkolith/Insider Trading/KURA/Form 4

Doyle Thomas James

SVP, Finance & AccountingKura Oncology, Inc. (KURA) · full profile →Form 4 · filed Sep 29, 2025
Net Selling
Open-Market Buys
$0
Open-Market Sells
$41K
Net Open-Market Flow
-$41K
Transactions
2
2 non-derivative · 0 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Sep 29, 2025Sell(S)5K$8.94$41K110K
Sep 27, 2025Grant(A)25K—$0114K

Transaction Codes

S
Open-market sale
A
Grant / award

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001193125-25-223662) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML